Showing 5521-5530 of 8473 results for "".
- Galderma Moves to Differentiate Their Two New HA Fillers From The Frayhttps://practicaldermatology.com/news/galderma-moves-to-differentiate-their-two-new-ha-fillers-from-the-fray/2458262/With a growing number of hyaluronic acid (HA) fillers available and even more in the pike, Galderma is highlighting how their two newest fillers --Restylane Refyne and Restylane Defyne --stand out from the crowd. In a word: flexibility. Th
- Obagi Medical Products Collaborates with Suzan Obagi, MD and Nextcell Medical to Introduce New Linehttps://practicaldermatology.com/news/obagi-medical-products-collaborates-with-suzan-obagi-md-and-nextcell-medical-to-introduce-new-line/2458274/Valeant Pharmaceuticals International, Inc.’s wholly owned subsidiary Obagi Medical Products collaborated with Nextcell Medical Company to claim exclusive distribution of Suzan Obagi, MD’s line of skin care products throughout the United States. Established in 2013 with cosmetic
- Save The Dates: ASLMS to Host 37th Annual Conference In Early April 2017https://practicaldermatology.com/news/save-the-dates-aslms-to-host-37th-annual-conference-in-early-april-2017/2458279/American Society for Laser Medicine and Surgery (ASLMS) 2017 will take place April 5 – 9, 2017 in San Diego, Calif. New for 2017 is a special CME Session, Moving from the Lab to the Clinic, which will focus on the translation of technolog
- Hologic to Acquire Cynosurehttps://practicaldermatology.com/news/hologic-to-acquire-cynosure/2458288/Hologic, Inc. and Cynosure, Inc. have signed a definitive agreement for Hologic to acquire all outstanding Cynosure shares for $66.00 per share in cash, which corresponds to an equity value of approximately $1.65 billi
- Alma Lasers' Accent Celebrates 10 Years with a New Campaignhttps://practicaldermatology.com/news/alma-lasers-accent-celebrates-10-years-with-a-new-campaign/2458294/Accent Prime is celebrating a 10 year anniversary with a newly launched campaign. Alma Lasers released the first generation of the Accent branded platform in 2007, with the FDA approval, and technologically enhanced it throughout the pas
- ZO Skin Health Introduces Oraser Cellulite Control Creamhttps://practicaldermatology.com/news/zo-skin-health-introduces-oraser-cellulite-control-cream/2458295/ZO Skin Health's new Oraser Cellulite Control is formulated to offer instant firming effects, visibly improve the skin's texture, and reduce the appearance of cellulite. In addition to smoothing skin and diminishing the "orange peel" appearance, the crème also helps impro
- Breaking Business News: ZO Skin Health, Inc. Acquires Refissa from Suneva Medicalhttps://practicaldermatology.com/news/business-news-zo-skin-health-inc-acquires-refissa-from-suneva-medical/2458298/ZO Skin Health, Inc. has acquired the worldwide rights to ReFissa as well as its generic equivalent tretinoin from Suneva Medical. Financial terms for the acquisition were not disclosed. ReFissa is the only
- Galderma's OTC Differin Gel Hits Store Shelveshttps://practicaldermatology.com/news/galdermas-otc-differin-gel-hits-stores/2458299/Galderma’s Differin Gel 0.1% (adapalene) is now available over the counter (OTC) at major retail and drug stores. Galderma officially launched the gel at a New York City media fete, and the skin care co
- Sun Pharma Introduces Leave Acne Behind Patient Initiativehttps://practicaldermatology.com/news/sun-pharma-introduces-leave-acne-behind-patient-initiative/2458310/Sun Pharma introudced a new initiative— “Leave Acne Behind™" — to educate patients and create awareness of severe recalcitrant nodular acne (SRNA). Sun Pharma reports that out of all of the prescription- treated acne cases today, 20 percent represent severe acne condi
- FDA Approves RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For Persistent Facial Erythema Associated With Rosaceahttps://practicaldermatology.com/news/fda-approves-rhofade-oxymetazoline-hydrochloride-cream-1-for-persistent-facial-erythema-associated-with-rosacea/2458315/The FDA has approved Allergan's RHOFADE™ cream for the topical treatment of persistent facial erythema associated with rosacea in adults. Approval was based on two clinical studies that evaluated the primary efficacy endpoint on day 29. Among the estimated 16 million aAmericans